常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.52/--
|
|
企业价值
101.73M
|
| 资产负债 |
|
每股账面净值
-1.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure. |

14.07 
